• Pharming’s October 27, 2026, third-quarter results call featured interim co-CEOs Kenneth Lynard and Leverne Marsh alongside Chief Medical Officer Anurag Relan.
• Management narrowed full-year revenue guidance to USD 380 million–390 million; operating expense guidance fell to USD 310 million–315 million.
• Quarterly revenue rose 21% to USD 117.6 million, supported by RUCONEST’s return to growth.
• Early inventory building contributed 9 percentage points of RUCONEST’s 14% growth, potentially affecting fourth-quarter revenue.
• Leniolisib’s CVID trial results are expected in November, informing a potential Phase III study following positive genetic immunodeficiency data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.